UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Tuberculosis transmission and control

Author
Kimon C Zachary, MD
Section Editor
C Fordham von Reyn, MD
Deputy Editor
Elinor L Baron, MD, DTMH

INTRODUCTION

The transmission of tuberculosis (TB) in healthcare facilities is an important public health concern; careful infection control measures are required to reduce healthcare-associated transmission [1].

Issues related to control of TB transmission will be reviewed here. Other issues related to TB are discussed in detail separately. (See related topics.)

TB TRANSMISSION

Person-to-person transmission of tuberculosis (TB) occurs via inhalation of droplet nuclei (airborne particles 1 to 5 microns in diameter). Coughing and singing facilitate formation of droplet nuclei [2-6]. (See "Natural history, microbiology, and pathogenesis of tuberculosis".)

Factors associated with risk for TB transmission via droplet nuclei include:

Presence of active untreated pulmonary or laryngeal TB

                 

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Wed Sep 28 00:00:00 GMT 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Jensen PA, Lambert LA, Iademarco MF, et al. Guidelines for preventing the transmission of Mycobacterium tuberculosis in health-care settings, 2005. MMWR Recomm Rep 2005; 54:1.
  2. Sepkowitz KA. How contagious is tuberculosis? Clin Infect Dis 1996; 23:954.
  3. Loudon RG, Spohn SK. Cough frequency and infectivity in patients with pulmonary tuberculosis. Am Rev Respir Dis 1969; 99:109.
  4. Loudon RG, Roberts RM. Droplet expulsion from the respiratory tract. Am Rev Respir Dis 1967; 95:435.
  5. Loudon RG, Roberts RM. Singing and the dissemination of tuberculosis. Am Rev Respir Dis 1968; 98:297.
  6. BATES JH, POTTS WE, LEWIS M. EPIDEMIOLOGY OF PRIMARY TUBERCULOSIS IN AN INDUSTRIAL SCHOOL. N Engl J Med 1965; 272:714.
  7. Tostmann A, Kik SV, Kalisvaart NA, et al. Tuberculosis transmission by patients with smear-negative pulmonary tuberculosis in a large cohort in the Netherlands. Clin Infect Dis 2008; 47:1135.
  8. O'Shea MK, Koh GC, Munang M, et al. Time-to-detection in culture predicts risk of Mycobacterium tuberculosis transmission: a cohort study. Clin Infect Dis 2014; 59:177.
  9. Dharmadhikari AS, Mphahlele M, Stoltz A, et al. Surgical face masks worn by patients with multidrug-resistant tuberculosis: impact on infectivity of air on a hospital ward. Am J Respir Crit Care Med 2012; 185:1104.
  10. Welbel SF, French AL, Bush P, et al. Protecting health care workers from tuberculosis: a 10-year experience. Am J Infect Control 2009; 37:668.
  11. Anger HA, Proops D, Harris TG, et al. Active case finding and prevention of tuberculosis among a cohort of contacts exposed to infectious tuberculosis cases in New York City. Clin Infect Dis 2012; 54:1287.
  12. Young KH, Ehman M, Reves R, et al. Tuberculosis Contact Investigations--United States, 2003-2012. MMWR Morb Mortal Wkly Rep 2016; 64:1369.
  13. Tokars JI, McKinley GF, Otten J, et al. Use and efficacy of tuberculosis infection control practices at hospitals with previous outbreaks of multidrug-resistant tuberculosis. Infect Control Hosp Epidemiol 2001; 22:449.
  14. Sutton PM, Nicas M, Harrison RJ. Tuberculosis isolation: comparison of written procedures and actual practices in three California hospitals. Infect Control Hosp Epidemiol 2000; 21:28.
  15. Dorman SE, Belknap R, Graviss EA, et al. Interferon-γ release assays and tuberculin skin testing for diagnosis of latent tuberculosis infection in healthcare workers in the United States. Am J Respir Crit Care Med 2014; 189:77.
  16. Zwerling A, Benedetti A, Cojocariu M, et al. Repeat IGRA testing in Canadian health workers: conversions or unexplained variability? PLoS One 2013; 8:e54748.
  17. Chaisson LH, Roemer M, Cantu D, et al. Impact of GeneXpert MTB/RIF assay on triage of respiratory isolation rooms for inpatients with presumed tuberculosis: a hypothetical trial. Clin Infect Dis 2014; 59:1353.
  18. Lippincott CK, Miller MB, Popowitch EB, et al. Xpert MTB/RIF assay shortens airborne isolation for hospitalized patients with presumptive tuberculosis in the United States. Clin Infect Dis 2014; 59:186.
  19. Moran GJ, Barrett TW, Mower WR, et al. Decision instrument for the isolation of pneumonia patients with suspected pulmonary tuberculosis admitted through US emergency departments. Ann Emerg Med 2009; 53:625.
  20. Centers for Disease Control and Prevention: Tuberculosis (TB) http://www.cdc.gov/tb/amplification_tests/amplification_tests.pdf (Accessed on January 20, 2008).
  21. Consensus statement on the use of Cepheid Xpert MTB/RIF® assay in making decisions to discontinue airborne infection isolation in healthcare settings. NTCA APHL, April 2016. http://www.tbcontrollers.org/docs/resources/NTCA_APHL_GeneXpert_Consensus_Statement_Final.pdf (Accessed on April 27, 2016).
  22. Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep 2009; 58:7.
  23. US Food and Drug Administration. New data shows test can help physicians remove patients with suspected TB from isolation earlier. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm434226.htm (Accessed on February 19, 2015).
  24. Revised Device Labeling for the Cepheid Xpert MTB/RIF Assay for Detecting Mycobacterium tuberculosis. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6407a8.htm?s_cid=mm6407a8_e (Accessed on February 26, 2015).
  25. Luetkemeyer A, Havlir D, Kendall M, et al. Xpert MTB/RIF Versus AFB Smear to Determine Respiratory Isolation of US TB Suspect. Abstract Number 824. CROI February 23-26, 2015 (Seattle, Washington). http://www.croiconference.org/sessions/xpert-mtbrif-versus-afb-smear-determine-respiratory-isolation-us-tb-suspects (Accessed on March 09, 2015).
  26. Campos M, Quartin A, Mendes E, et al. Feasibility of shortening respiratory isolation with a single sputum nucleic acid amplification test. Am J Respir Crit Care Med 2008; 178:300.
  27. Fløe A, Hilberg O, Thomsen VØ, et al. Shortening Isolation of Patients With Suspected Tuberculosis by Using Polymerase Chain Reaction Analysis: A Nationwide Cross-sectional Study. Clin Infect Dis 2015; 61:1365.
  28. Cepheid. Xpert MTB/RIF assay [package insert]. Cepheid, Sunnyvale, CA 2015. www.cepheid.com/mtbrif-pi (Accessed on June 13, 2016).
  29. Division of Microbiology Devices, Office of In Vitro Diagnostics and Radiological Health, Center for Devices and Radiological Health, Food and Drug Administration, Centers for Disease Control and Prevention (CDC). Revised device labeling for the Cepheid Xpert MTB/RIF assay for detecting Mycobacterium tuberculosis. MMWR Morb Mortal Wkly Rep 2015; 64:193.